Covea Finance Acquires Shares of 81,101 Edwards Lifesciences Corporation $EW

Covea Finance bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 81,101 shares of the medical research company’s stock, valued at approximately $6,307,000.

Several other large investors have also recently modified their holdings of EW. Quantbot Technologies LP purchased a new stake in shares of Edwards Lifesciences during the 1st quarter valued at approximately $26,000. Rosenberg Matthew Hamilton bought a new stake in Edwards Lifesciences during the 2nd quarter valued at $28,000. NewSquare Capital LLC raised its holdings in Edwards Lifesciences by 57.8% during the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 134 shares during the period. Rakuten Securities Inc. lifted its position in shares of Edwards Lifesciences by 413.7% during the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after acquiring an additional 302 shares in the last quarter. Finally, Riverview Trust Co boosted its holdings in shares of Edwards Lifesciences by 44.5% in the second quarter. Riverview Trust Co now owns 516 shares of the medical research company’s stock worth $40,000 after acquiring an additional 159 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

EW has been the topic of a number of analyst reports. Sanford C. Bernstein reiterated a “market perform” rating and set a $90.00 price objective on shares of Edwards Lifesciences in a research note on Monday, November 3rd. Jefferies Financial Group set a $98.00 target price on Edwards Lifesciences and gave the company a “buy” rating in a report on Wednesday, October 29th. Piper Sandler reissued an “overweight” rating and issued a $95.00 price target (up from $90.00) on shares of Edwards Lifesciences in a report on Friday, October 31st. Robert W. Baird set a $87.00 price objective on shares of Edwards Lifesciences and gave the company a “neutral” rating in a research note on Tuesday, December 16th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, October 8th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $93.95.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $84.03, for a total value of $85,626.57. Following the completion of the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,848,828.06. The trade was a 4.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 11,386 shares of the stock in a transaction on Friday, December 12th. The shares were sold at an average price of $83.76, for a total value of $953,691.36. Following the completion of the transaction, the vice president directly owned 38,970 shares in the company, valued at approximately $3,264,127.20. This represents a 22.61% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 45,465 shares of company stock valued at $3,804,610. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Up 0.1%

Shares of NYSE EW opened at $86.29 on Friday. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average of $83.60 and a 200-day moving average of $79.51. The firm has a market capitalization of $50.07 billion, a price-to-earnings ratio of 37.19, a PEG ratio of 3.88 and a beta of 0.97. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The business had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period in the previous year, the business posted $0.67 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Sell-side analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.